Getting Started with Aeolus Products
Case 1: Recreating the Complex Tumor Microenvironment with Vascularized Organoids-on-a-Chip
Technical Approach & Aeolus Innovation's Products:
This pioneering study leveraged a multi-chip strategy to build and mature the model:
1. Initial Vascular Network Formation (Using the Lateral Co-culture Chip): Patient-derived tumor organoids were loaded into the central gel channel. Endothelial cells were introduced into the adjacent side flow channels. Over several days, these cells spontaneously formed primitive capillary-like networks that infiltrated and surrounded the tumor organoid, establishing an initial tumor-vasculature interface.
2. Maturation and Perfusion Validation (Using the Perfusion Ring Chip): The pre-vascularized constructs were then transferred to the Perfusion Ring Chip for long-term maturation under continuous, low-shear flow. To demonstrate functional perfusion, fluorescent microbeads were introduced into the circulating medium. Real-time imaging confirmed the beads moving through the endothelial networks, providing direct visual proof of a patent, perfusable vasculature within the tumor organoid.
Case 2: Reconstruction of Complex Tumor Organoid Microenvironment: Immunococulture Technology
Aeolus Innovation's microarray and co-culture chips enable the establishment of an ex vivo activated PBMC-tumor organoid co-culture model, which effectively assesses immune cell-mediated tumoroid killing and provides a robust technological platform for validating immunotherapy drugs.
1. Functional Immune Killing Assay: The platform successfully enabled real-time monitoring and quantitative analysis of immune-mediated tumoroid killing. Metrics such as tumor organoid viability, size reduction, and immune cell infiltration could be tracked over time.
2. Versatile Drug Testing Platform: This model serves as a powerful tool for the in vitro validation of a wide range of immunotherapeutics, including checkpoint inhibitors, bispecific antibodies, and CAR-T cells, by measuring their ability to enhance immune cell cytotoxicity.
3. Precision Immunology Insights: By using patient-matched tumor organoids and autologous immune cells, the system provides a framework for studying patient-specific immune responses and predicting clinical outcomes to immunotherapies.
Case 3: High-Throughput Organoid Generation via Microdroplet Technology
This study utilized a dedicated microfluidic droplet generation chip from AvelusInnovation. The chip employs precise flow-focusing geometry to encapsulate single cells or small cell aggregates within monodisperse droplets of a hydrogel precursor (e.g., Matrigel or synthetic ECM). These uniform droplets, acting as individual micro-bioreactors, are then collected and cultured in bulk.
1. High-Throughput Susceptibility Testing: It enables the simultaneous generation of thousands of identical organoid precursors per run, creating the large-scale, consistent samples required for high-content drug screens and robust statistical analysis.
2. Significant Reagent Reduction: By miniaturizing each organoid into a nanoliter-scale droplet, the consumption of critical and expensive extracellular matrix components (e.g., Matrigel) is dramatically reduced, lowering costs per assay.
3. Enhanced Uniformity & Control: The microfluidic process ensures highly consistent droplet size, leading to improved size and maturity homogeneity across the organoid population, which is critical for reproducible experimental data.
Case 4: Achieving Precise Control and Monitoring in Organoid Culture through Integrated Sensors
This research integrates Aeolus Innovation's suite of miniaturized, chip-compatible biosensors directly into our Perfusion Ring Chip and Automated Incubator Module. A modular sensor array continuously tracks key metabolic and physiological parameters within the culture, including pH, dissolved oxygen (O₂), glucose/lactate levels, and specific secreted biomarkers (e.g., cytokines). This data is streamed in real-time to a central dashboard, providing a live metabolic readout of organoid health and activity.
1. Unprecedented Process Control: Researchers can now move beyond inferring conditions from the bulk medium to directly measuring the microenvironment at the organoid surface, allowing for proactive adjustment of perfusion rates or media composition to maintain optimal conditions.
2. Data-Rich Kinetic Profiles: The system generates continuous kinetic data on organoid metabolism and secretory profiles, revealing dynamic responses to drugs or genetic perturbations that would be missed by traditional endpoint assays.
3. Enhanced Reproducibility & Quality Assurance: Constant monitoring ensures culture conditions remain within strict parameters, dramatically improving batch-to-batch consistency and allowing for the early detection of contamination or culture failure.
4. Predictive Insights: Correlating real-time metabolic shifts (e.g., a drop in glucose coupled with a rise in lactate) with subsequent phenotypic outcomes helps build predictive models of organoid viability, maturation, and drug response.